What do we know from clinical trials on exercise and Alzheimer's disease?

J Sport Health Sci

Center for Hormone Advanced Science and Education, Roskamp Institute, Sarasota, FL 34243, USA.

Published: December 2016

Alzheimer's disease (AD) is the most common form of dementia in elderly with major symptoms of a general term for memory loss and other intellectual abilities impairment which are serious enough to interfere with daily life. While there is no treatment can prevent and revise the cognitive function impairment in AD, physical activity becomes a potential beneficial intervention for AD. Multiple evidences suggested that exercise in general plays beneficial roles in improving brain function. Most common mechanisms of exercise-induced enhancement of brain function are including alteration of neurogenesis, neuron plasticity, neuronal signaling and receptors, as well as neuronal networks. This mini review includes most recent clinical studies and focuses on the effects of physical exercise, cognitive stimulation, and combination of both physical and cognitive training on protection and rescue cognitive decline in people with AD.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679699PMC
http://dx.doi.org/10.1016/j.jshs.2016.10.002DOI Listing

Publication Analysis

Top Keywords

brain function
8
clinical trials
4
trials exercise
4
exercise alzheimer's
4
alzheimer's disease?
4
disease? alzheimer's
4
alzheimer's disease
4
disease common
4
common form
4
form dementia
4

Similar Publications

Background: Although impaired cognitive control is common during the acute detoxification phase of substance use disorders (SUD) and is considered a major cause of relapse, it remains unclear after prolonged methadone maintenance treatment (MMT). The aim of the present study was to elucidate cognitive control in individuals with heroin use disorder (HUD) after prolonged MMT and its association with previous relapse.

Methods: A total of 63 HUD subjects (41 subjects with previous relapse and 22 non-relapse subjects, mean MMT duration: 12.

View Article and Find Full Text PDF

Hyponatremia is associated with malignant brain edema after mechanical thrombectomy in acute ischemic stroke.

BMC Neurol

January 2025

Neurological Disorder Center, Department of Cerebrovascular Disease, Suining Central Hospital, Sichuan, 629000, China.

Background: Hyponatremia (< 135 mmol/L) is the most common electrolyte disturbance in patients with stroke. However, few studies have reported the relationship between hyponatremia at admission and outcomes in patients with acute ischemic stroke (AIS) treated with mechanical thrombectomy (MT). This study is aimed to explore the association between hyponatremia and clinical outcomes following MT.

View Article and Find Full Text PDF

MHNet: Multi-view High-Order Network for Diagnosing Neurodevelopmental Disorders Using Resting-State fMRI.

J Imaging Inform Med

January 2025

Department of Chinese and Bilingual Studies, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong Special Administrative Region, China.

Deep learning models have shown promise in diagnosing neurodevelopmental disorders (NDD) like ASD and ADHD. However, many models either use graph neural networks (GNN) to construct single-level brain functional networks (BFNs) or employ spatial convolution filtering for local information extraction from rs-fMRI data, often neglecting high-order features crucial for NDD classification. We introduce a Multi-view High-order Network (MHNet) to capture hierarchical and high-order features from multi-view BFNs derived from rs-fMRI data for NDD prediction.

View Article and Find Full Text PDF

This study investigates post-stroke cognitive impairment (PSCI) by utilizing spectral dynamic causal modeling (spDCM) to examine changes in effective connectivity (EC) within the default mode, executive control, dorsal attention, and salience networks. Forty-one PSCI patients and 41 demographically matched healthy controls underwent 3D-T1WI and resting-state functional magnetic resonance imaging on a 3.0T MRI.

View Article and Find Full Text PDF

Esketamine, a newly developed antidepressant, is the subject of this research which seeks to explore its impact on depressive symptoms in neuropathic pain mice and the potential molecular mechanisms involved. Through transcriptome sequencing and bioinformatics analysis combined with in vivo studies, it was identified that esketamine markedly boosts the levels of the m6A methyltransferase METTL3 and the AMPA receptor GluA1 subunit. Esketamine activates METTL3, allowing it to bind with GluA1 mRNA, promoting m6A modification, thereby enhancing GluA1 expression at synapses.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!